Article Information
History
- March 3, 2021.
Article Versions
- Version 1 (September 25, 2020 - 04:54).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Katherine L. McNamara1,2,3,
- Jennifer L. Caswell-Jin1,
- Rohan Joshi4,
- Zhicheng Ma2,
- Eran Kotler3,
- Gregory R. Bean4,
- Michelle Kriner5,
- Zoey Zhou5,
- Margaret Hoang5,
- Joseph Beechem5,
- Jason Zoeller6,
- Michael F. Press7,
- Dennis J. Slamon8,
- Sara A. Hurvitz8 and
- Christina Curtis1,2,3,*
- 1Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, California, USA
- 2Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California, USA
- 3Department of Genetics, Stanford University School of Medicine, Stanford, California, USA
- 4Department of Pathology, Stanford University School of Medicine, Stanford, California, USA
- 5NanoString Technologies, Seattle, Washington USA
- 6Department of Cell Biology, Harvard Medical School, Boston, MA
- 7Department of Pathology, Keck School of Medicine of USC, Los Angeles, California, USA
- 8David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA
- ↵*Corresponding Author: Christina Curtis, PhD, Stanford University School of Medicine, 265 Campus Drive, Lorry Lokey Building Suite G2120C, Stanford, CA 94305, (650) 498-9943, Email: cncurtis{at}stanford.edu
Posted March 03, 2021.
Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response
